ClinicalTrials.gg

Melanoma clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 3,373 studies for Melanoma across more than 10 countries. 580 are recruiting or about to start. 2,442 of them are mainly about Melanoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 3 narrower conditions too, such as Uveal Melanoma: 3,542 studies, 609 open.

ClinicalTrials.gov finds 3,784 studies for Melanoma. How that becomes 3,372 here

This page counts the studies the registry files under Melanoma, and those it files under no condition that list Melanomathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 3,784Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −168Filed under a narrower condition, counted on its own pageUveal Melanoma 157 · Dysplastic Nevus Syndrome 10
  3. −67List Melanoma as a condition, but the registry did not file them under itMost often written as “Advanced Melanoma” (16), “Clinical Stage III Cutaneous Melanoma AJCC v8” (6), and “Cutaneous Malignant Melanoma” (5). The registry filed them under other conditions only, most often Colorectal Neoplasms (11) and Melanoma, Cutaneous Malignant (10).
  4. −177Match it another way50 name it in the title, 7 in a keyword, and 120 by a synonym or other text the search reads.
  5. 3,372The count on this page171 of them list Melanoma in their own words; the registry filed them under no condition.

Status

Completed
1,571
Terminated
524
Recruiting
467
Active, not recruiting
288
Status unknown
252
Withdrawn
119

Phase

Phase 2
1,425
Phase 1
1,264
Phase 3
193
Early Phase 1
58
Phase 4
28

Where

United States
2,049
France
362
Australia
285
Germany
284
Spain
282
United Kingdom
269

Who develops what

Add Melanoma to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 82 programs from 59 companies, 45 with this as their studies’ main aim; 9 with a live phase 3 study; 16 primary completions in the next 12 months. Compare Pfizer, Bristol-Myers Squibb and BioNTech here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
pembrolizumabRecent, repeated
Evidence
  • NCT07749586 · Arvinas Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2026
  • NCT07565285 · Primmune Therapeutics, Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Apr 2026
  • NCT07751042 · Strand Therapeutics Inc. · Phase 2 · live · background · “KEYTRUDA®” · registered Apr 2026
  • NCT07287917 · Aminex Therapeutics, Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Nov 2025
  • NCT06984328 · Genmab · Phase 2 · background · “Pembrolizumab” · registered May 2025
Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015)1921 studies
NivolumabRecent, repeated
Evidence
  • NCT07815574 · Scancell Ltd · Phase 3 · live · background · “Nivolumab & Ipilimumab” · registered Sep 2026
  • NCT06640530 · Biocad · Phase 3 · live · comparator · “Opdivo” · registered Oct 2024
  • NCT06587451 · Sandoz · Phase 3 · comparator · “Opdivo-EU (Induction)” · registered Aug 2024
  • NCT06581406 · Replimune Inc. · Phase 3 · live · background · “Nivolumab” · registered Aug 2024
  • NCT06362369 · 7 Hills Pharma, LLC · Phase 2 · live · background · “Nivolumab” · registered Mar 2024
Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015)1517 studies
IpilimumabRecent, repeated
Evidence
  • NCT07815574 · Scancell Ltd · Phase 3 · live · background · “Nivolumab & Ipilimumab” · registered Sep 2026
  • NCT06784648 · BioInvent International AB · Phase 2 · live · background · “Ipilimumab (YervoyTM, 50 mg/10 mL solution)” · registered Dec 2024
  • NCT06587451 · Sandoz · Phase 3 · background · “Yervoy-EU (Induction)” · registered Aug 2024
  • NCT06581406 · Replimune Inc. · Phase 3 · live · comparator · “Ipilimumab” · registered Aug 2024
  • NCT06362369 · 7 Hills Pharma, LLC · Phase 2 · live · background · “Ipilimumab” · registered Mar 2024
Bristol-Myers Squibb91% of its industry studiesUS: Bristol-Myers Squibb (FDA 2011)EU: Bristol-Myers Squibb (EMA 2011)88 studies
PaclitaxelRecent, repeated
Evidence
  • NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Paclitaxel” · registered Mar 2026
  • NCT07310784 · Suzhou BlueHorse Therapeutics Co., Ltd. · Phase 2 · live · comparator · “Dacarbazine, temozolomide, paclitaxel, carboplatin/cisplatin” · registered Dec 2025
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Paclitaxel” · registered Aug 2023
  • NCT05824975 · GI Innovation, Inc. · Phase 2 · live · background · “paclitaxel” · registered Mar 2023
  • NCT04752826 · BioInvent International AB · Phase 2 · live · background · “Paclitaxel 80 mg/m2 weekly” · registered Dec 2020
Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed44 studies
TemozolomideRecent, repeated
Evidence
  • NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Temozolomide” · registered Mar 2026
  • NCT07310784 · Suzhou BlueHorse Therapeutics Co., Ltd. · Phase 2 · live · comparator · “Dacarbazine, temozolomide, paclitaxel, carboplatin/cisplatin” · registered Dec 2025
  • NCT06346067 · Erasca, Inc. · Phase 3 · live · comparator · “Temozolomide” · registered Mar 2024
  • NCT05647954 · Taizhou Hanzhong biomedical co. LTD · Phase 3 · live · comparator · “Temozolomide + TACE” · registered Nov 2022
  • NCT04478279 · Sapience Therapeutics · Phase 2 · live · background · “Temozolomide” · registered Jul 2020
Merck & Co., Inc23% of its industry studiesUS: off-patent, 7 generics marketedEU: off-patent, 4 generics authorized44 studies
CarboplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Carboplatin” · registered Mar 2026
  • NCT07310784 · Suzhou BlueHorse Therapeutics Co., Ltd. · Phase 2 · live · comparator · “Dacarbazine, temozolomide, paclitaxel, carboplatin/cisplatin” · registered Dec 2025
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Carboplatin” · registered Aug 2023
  • NCT04993677 · Pfizer · Phase 2 · background · “carboplatin” · registered Jul 2021
  • NCT04083599 · Genmab · Phase 2 · live · background · “Carboplatin” · registered Sep 2019
Eli Lilly and Company16% of its industry studies33 studies
DacarbazineRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07310784 · Suzhou BlueHorse Therapeutics Co., Ltd. · Phase 2 · live · comparator · “Dacarbazine, temozolomide, paclitaxel, carboplatin/cisplatin” · registered Dec 2025
  • NCT06346067 · Erasca, Inc. · Phase 3 · live · comparator · “Dacarbazine” · registered Mar 2024
  • NCT05987332 · IDEAYA Biosciences · Phase 3 · live · comparator · “Dacarbazine” · registered Jul 2023
  • NCT04200040 · OrienGene Biotechnology Ltd. · Phase 2 · comparator · “Dacarbazine (DTIC)” · registered Dec 2019
  • NCT03070392 · Immunocore Ltd · Phase 2 · comparator · “Dacarbazine” · registered Feb 2017
Bristol-Myers Squibb21% of its industry studies33 studies
relatlimabRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT06246916 · Regeneron Pharmaceuticals · Phase 3 · live · comparator · “relatlimab+nivolumab” · registered Jan 2024
  • NCT06264180 · Replimune Inc. · Phase 3 · live · comparator · “Nivolumab + Relatlimab” · registered Jan 2024
  • NCT06112314 · Immunocore Ltd · Phase 3 · live · comparator · “Nivolumab + Relatlimab” · registered Oct 2023
Bristol-Myers Squibb100% of its industry studies33 studies
toripalimabRecent, repeated
Evidence
  • NCT07099430 · Nanjing Leads Biolabs Co.,Ltd · Phase 2 · live · background · “Toripalimab Injection” · registered Jul 2025
  • NCT05955105 · Innolake Biopharm · Phase 2 · live · background · “Toripalimab” · registered Jul 2023
  • NCT05723432 · Shanghai Kanda Biotechnology Co., Ltd. · Phase 2 · live · background · “Toripalimab” · registered Feb 2023
RemeGen Co., Ltd.15% of its industry studiesUS: Coherus Biosciences, Inc. (FDA 2023)EU: Topalliance Biosciences Europe Limited (EMA 2024)33 studies
PemetrexedRecent, repeated
Evidence
  • NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Pemetrexed” · registered Mar 2026
  • NCT05180799 · BioAtla, Inc. · Phase 2 · live · background · “Pemetrexed (Alimta)” · registered Dec 2021
  • NCT04993677 · Pfizer · Phase 2 · background · “pemetrexed” · registered Jul 2021
  • NCT04198766 · Inhibrx Biosciences, Inc · Phase 2 · live · background · “Pemetrexed 500 mg/m2” · registered Dec 2019
  • NCT04083599 · Genmab · Phase 2 · live · background · “Pemetrexed” · registered Sep 2019
Eli Lilly and Company67% of its industry studiesUS: off-patent, 4 generics marketedEU: off-patent, 3 generics authorized22 studies
CisplatinRecent, repeated
Evidence
  • NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Cisplatin” · registered Mar 2026
  • NCT07310784 · Suzhou BlueHorse Therapeutics Co., Ltd. · Phase 2 · live · comparator · “Dacarbazine, temozolomide, paclitaxel, carboplatin/cisplatin” · registered Dec 2025
  • NCT04198766 · Inhibrx Biosciences, Inc · Phase 2 · live · background · “Cisplatin 75mg/m2” · registered Dec 2019
  • NCT04083599 · Genmab · Phase 2 · live · background · “Cisplatin” · registered Sep 2019
  • NCT03645928 · Iovance Biotherapeutics, Inc. · Phase 2 · background · “Cisplatin” · registered Aug 2018
Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed22 studies
BevacizumabRecent, repeated
Evidence
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Bevacizumab” · registered Aug 2023
  • NCT05824975 · GI Innovation, Inc. · Phase 2 · live · background · “bevacizumab” · registered Mar 2023
  • NCT03167177 · ImmunityBio, Inc. · Phase 2 · background · “Bevacizumab” · registered May 2017
Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others22 studies
trametinibRecent, repeated
Evidence
  • NCT06346067 · Erasca, Inc. · Phase 3 · live · background · “Trametinib” · registered Mar 2024
  • NCT05275374 · Xynomic Pharmaceuticals, Inc. · Phase 2 · live · background · “Trametinib” · registered Feb 2022
  • NCT02967692 · Novartis · Phase 3 · background · “Trametinib” · registered Nov 2016
  • NCT01072175 · Novartis · Phase 2 · background · “GSK1120212” · registered Feb 2010
GlaxoSmithKline49% of its industry studiesEU: Novartis (EMA 2014)22 studies
cemiplimabRecent, repeated
Evidence
  • NCT06090266 · OncoResponse, Inc. · Phase 2 · live · background · “Cemiplimab” · registered Sep 2023
  • NCT05259696 · Palleon Pharmaceuticals, Inc. · Phase 2 · background · “Cemiplimab” · registered Feb 2022
  • NCT05094804 · OncoResponse, Inc. · Phase 2 · live · background · “Cemiplimab” · registered Sep 2021
  • NCT04913220 · Sanofi · Phase 2 · background · “Cemiplimab” · registered May 2021
  • NCT03684785 · Exicure, Inc. · Phase 2 · background · “Cemiplimab” · registered Sep 2018
Regeneron Pharmaceuticals83% of its industry studiesUS: Regeneron Pharmaceuticals (FDA 2018)EU: Regeneron Pharmaceuticals (EMA 2019)22 studies
enzalutamideRecent, repeated
Evidence
  • NCT05914116 · DualityBio Inc. · Phase 2 · live · background · “Enzalutamide” · registered Jun 2023
  • NCT05551117 · MacroGenics · Phase 2 · comparator · “Enzalutamide” · registered Sep 2022
Astellas Pharma Inc45% of its industry studiesUS: Astellas Pharma Inc (FDA 2012)EU: off-patent, 1 generic authorized22 studies
Abiraterone AcetateRecent, repeated
Evidence
  • NCT05914116 · DualityBio Inc. · Phase 2 · live · background · “Abiraterone” · registered Jun 2023
  • NCT05551117 · MacroGenics · Phase 2 · comparator · “Abiraterone” · registered Sep 2022
Johnson & Johnson65% of its industry studiesUS: off-patent, 11 generics marketedEU: off-patent, 2 generics authorized22 studies

43 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
fianlimab☆ Track3 live phase-3 studies: NCT05608291, NCT06246916, NCT05352672Regeneron Pharmaceuticals
cemiplimabApproved: US 2018 · EU 2019☆ Track1 live phase-3 study: NCT06246916Regeneron Pharmaceuticals
lifileucel☆ Track1 live phase-3 study: NCT05727904Iovance Biotherapeutics, Inc.
iSCIB1+☆ Track1 live phase-3 study: NCT07815574Scancell Ltd
intismeran autogene☆ Track1 live phase-3 study: NCT05933577Merck & Co., Inc

The 5 in phase 3 with the nearest primary completion, of 82 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (16)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 30 Nov 2026 est.KRAS G12D Degrader ARV-806 · Arvinas Inc. · Phase 2 registry mapping onlyNCT07023731 A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation — primary endpoint: Part A (Phase 1): Number of dose-limiting toxicities (DLTs) of ARV-806 · 76 enrolled
  • 30 Nov 2026 est.Anti-PD-1/IL-15 Fusion Protein JMT108 · CSPC Pharmaceutical Group Limited · Phase 2 main aimNCT07280832 Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors — primary endpoint: Dose-Limiting Toxicity (DLT) (Phase I) · 500 enrolled
  • 15 Dec 2026 est.Anti-IGSF8 Monoclonal Antibody GV20-0251 · GV20 Therapeutics · Phase 2 named, not the main aimNCT05669430 A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies — primary endpoint: Objective Response Rate ORR per RECIST version 1.1 (Parts B and D) · 365 enrolled

13 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Melanoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 78 open · Tyrosine kinase inhibitors (TKIs) 14 open · Alkylating agents 7 open · Antimetabolites 6 open · Antibody-drug conjugates (ADCs) 3 open

Coming up

250studies finish main data collection within a year11 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger. 47 (10%) take children under 18. 2 (<1%) are for women only and 1 (<1%) for men only; 29 (6%) take healthy volunteers.

Recruiting studies that take each age, of 467
AgeWomenMen
1039 (8%)38 (8%)
18451 (97%)451 (97%)
30453 (97%)452 (97%)
40451 (97%)450 (96%)
50449 (96%)449 (96%)
65449 (96%)449 (96%)
75440 (94%)440 (94%)
85407 (87%)408 (87%)

Across all 3,373 studies, recruiting or not: 10% stop at 75 or younger and 3% at 65; 10% take children; 1% are for women only and <1% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Melanoma studies take

Of 411 phase 1 interventional studies under Melanoma, half reached primary completion within 49 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 149 mo31–76 · 411 studies46 mo28–66 · 225 studies52 mo33–82 · 186 studies
Phase 1/261 mo42–85 · 220 studies61 mo41–84 · 135 studies59 mo47–98 · 85 studies
Phase 253 mo32–90 · 384 studies35 mo26–60 · 106 studies67 mo41–94 · 278 studies
Phase 347 mo30–94 · 95 studies37 mo25–49 · 64 studies—
Interventional, no phase38 mo20–62 · 227 studies—39 mo20–62 · 219 studies
Observational71 mo35–248 · 236 studies42 mo30–80 · 59 studies178 mo40–320 · 177 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 3,373. Browse all 3,373 → or search them.